Entos Pharmaceuticals
PrivateLast Round
Grant
Aug 1, 2025
Total Funding Raised
$126.85M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Entos Pharmaceuticals operates in Healthcare & Life Sciences and is based in Edmonton. Its latest recorded funding round was a Grant round in August 2025.
Entos Pharmaceuticals is a biotechnology company developing genetic medicines using its proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Entos Pharmaceuticals Comparables
Compare Entos Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NanoVation Therapeutics | 89% | |
| Acuitas Therapeutics | 87% | |
| Genevant Sciences | 87% |
For institutional investors. Book with your work email.
Entos Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 1, 2025 | ||||
| VC Round | May 22, 2025 | ||||
| Grant | Mar 11, 2025 | ||||
| Grant | Feb 5, 2025 | ||||
| Grant | Oct 7, 2023 | ||||
Grant | Oct 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Entos Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Canadian Institutes of Health Research | Grant |
| Canadian International Innovation Program | Grant |
| CureDuchenne Ventures | VC Round |
| National Research Council Canada Industrial Research Assistance Program | Grant |
| National Research Council Canada | Grant |
| Government of Canada | Grant |
| California Institute for Regenerative Medicine | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 32% MoM.
- Apr 20, 2026
Developing a curative therapy for LMNA-Related Congenital Muscular Dystrophy.
For institutional investors. Book with your work email.
Entos Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Entos Pharmaceuticals's valuation, stock price, and market status.
Is Entos Pharmaceuticals a public or private company?
Entos Pharmaceuticals is a private company.
What is the current stock price of Entos Pharmaceuticals?
Entos Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Entos Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Entos Pharmaceuticals worth (valuation)?
Valuation information for Entos Pharmaceuticals is not publicly available.
Can I buy Entos Pharmaceuticals stock?
Entos Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Entos Pharmaceuticals's last funding round?
Entos Pharmaceuticals's most recent funding round was Grant on August 1, 2025.
Who are the main investors in Entos Pharmaceuticals?
Key investors in Entos Pharmaceuticals include CureDuchenne Ventures.
Will Entos Pharmaceuticals IPO soon?
No public IPO plans have been announced for Entos Pharmaceuticals.
How can I track Entos Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Entos Pharmaceuticals's shares on secondary markets.